Overview

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

Status:
Completed
Trial end date:
2019-02-21
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Arrevus Inc.
Cempra Inc
Treatments:
Anti-Bacterial Agents
Fusidic Acid